459 related articles for article (PubMed ID: 23414607)
41. Costimulatory wars: the tumor menace.
Hurwitz AA; Kwon ED; van Elsas A
Curr Opin Immunol; 2000 Oct; 12(5):589-96. PubMed ID: 11007364
[TBL] [Abstract][Full Text] [Related]
42. T-cell-independent antitumor effects of CD40 ligation.
Rakhmilevich AL; Alderson KL; Sondel PM
Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
[TBL] [Abstract][Full Text] [Related]
43. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
44. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
[TBL] [Abstract][Full Text] [Related]
45. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
46. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
47. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
48. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.
Madireddi S; Eun SY; Lee SW; Nemčovičová I; Mehta AK; Zajonc DM; Nishi N; Niki T; Hirashima M; Croft M
J Exp Med; 2014 Jun; 211(7):1433-48. PubMed ID: 24958847
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
[TBL] [Abstract][Full Text] [Related]
51. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
52. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
53. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.
Buchan SL; Rogel A; Al-Shamkhani A
Blood; 2018 Jan; 131(1):39-48. PubMed ID: 29118006
[TBL] [Abstract][Full Text] [Related]
54. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
55. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota.
Blake SJ; James J; Ryan FJ; Caparros-Martin J; Eden GL; Tee YC; Salamon JR; Benson SC; Tumes DJ; Sribnaia A; Stevens NE; Finnie JW; Kobayashi H; White DL; Wesselingh SL; O'Gara F; Lynn MA; Lynn DJ
Cell Rep Med; 2021 Dec; 2(12):100464. PubMed ID: 35028606
[TBL] [Abstract][Full Text] [Related]
56. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
[TBL] [Abstract][Full Text] [Related]
57. The Immune Revolution: A Case for Priming, Not Checkpoint.
Vonderheide RH
Cancer Cell; 2018 Apr; 33(4):563-569. PubMed ID: 29634944
[TBL] [Abstract][Full Text] [Related]
58. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
[TBL] [Abstract][Full Text] [Related]
59. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells.
Burocchi A; Pittoni P; Gorzanelli A; Colombo MP; Piconese S
Eur J Immunol; 2011 Dec; 41(12):3615-26. PubMed ID: 22229156
[TBL] [Abstract][Full Text] [Related]
60. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
